Απ: replicel - νομιζω καλα νεα
Παιδια, συγνωμη, αλλα ας μην ελπιζουμε υπερβολικα πολυ, οπως κι εγω συχνα ατυχως κανω..
Εμενα ολα μπαρμπουτσαλα μου φαινονται, πιο πιθανο ειναι μεσα απο το σαιτ μας να βρεθει λυση παρα απο τα διαφορα λαμογια.. Μας εχουν σαν τις καλντεριμιτζουδες της παλιας εποχης στην Τρουμπα, που περιμενουν απεγνωσμενα καποιον αγαπησιαρη πελατη, να τις βγαλει απο τη θλιβερη ζωη τους... Ολοι απατεωνες ειναι, ολα τα- απο παρενεργειες- φαρμακα ειναι προσωρινα ημιμετρα για οσους προλαβαν την κατασταση, η πορεια ειναι προδιαγεγραμμενη, τουλαχιστον ας το γνωριζουμε αυτο κι υστερα ας κανουμε οτι μας φωτισει ο Βουδας.... Μακαρι, μακαρι να γινει κατι, αλλα να γινει συντομα.. Μακαρι...
Η απογοητευση για το παραπανω δημοσιευμα, που ειχε βγει και πριν χρονια οπως σωστα επισημανθηκε, προερχεται απο το σαιτ της replicel βλ.
http://www.replicel.com/replicel-update-on-first-in-human-clinical-trial-ts001-2009/
Η ιδια η εταιρεια λοιπον στη σημειωση της μας προσγειωνει σε....φαραγγι... I'm sorry παιδια....
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and can include, without limitation, statements based on current expectations involving a number of risks and uncertainties which are not guarantees of future performance of the Company such as the statement that the RepliCelTM hair cell replication technology has the potential to become the world’s first minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women and statements with respect to the anticipated timing for injections and data analysis. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company’s clinical trials, including that the Company’s hair cell replication technology may not work as planned or may not be effective at causing the re-growth of hair follicles or the rejuvenation of damaged, miniaturized follicles; the effects of government regulation on the Company’s business; the viability and marketability of the Company’s hair cell replication technology; the Company’s failure to successfully implement its marketing plan; the development of superior technology by the Company’s competitors; the failure of consumers and the medical community to accept the Company’s technology as safe and effective; risks associated with the Company’s ability to obtain and protect rights to our intellectual property; risks and uncertainties associated with the Company’s ability to raise additional capital; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2010 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at
www.sec.gov and with the Canadian Securities Commissions on Sedar at
www.sedar.com.
